BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. stock has experienced significant events and fluctuations over the past six months. The share price saw a substantial increase of 318.81% from March 27, 2025, to March 26, 2026. Key events impacting the stock include reporting interim Phase 1 findings for BGE-102, Eli Lilly's announcement of its intention to acquire Ventyx, expansion of the indication for BGE-102 to include diabetic macular edema, announcement of the pricing of an upsized $115.0 million public offering, presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, reporting its Full Year 2025 Financial Results, presentation at the Piper Sandler 37th Annual Healthcare Conference, and presentation at the Jefferies Global Healthcare Conference.

As a clinical-stage biopharmaceutical company, BioAge Labs, Inc. does not currently have commercialized products or services on the market, so there is no discernible demand seasonality. Demand for its future products will be driven by clinical trial success, regulatory approvals, and market adoption, rather than seasonal patterns.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases by targeting the biology of human aging. The company's lead product candidate, BGE-102, is in Phase 1 clinical trials for atherosclerotic cardiovascular disease, diabetic macular edema, and geographic atrophy. BioAge Labs is also developing APJ agonists for obesity and has preclinical programs leveraging its discovery platform. The company has a collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets related to aging.

BioAge Labs, Inc. is headquartered in Richmond and Emeryville, California. Its operations are focused on research and development, with no broad commercial geographic footprint for product sales at this time.

BioAge Labs maintains a reputation as a clinical-stage biopharmaceutical company focused on an innovative approach to metabolic diseases by targeting aging. Analyst sentiment for BIOA is generally positive, with a consensus rating of "Moderate Buy" and a consensus price target of $46.25. The company faces inherent risks as a clinical-stage biotech, and the stock is considered speculative due to BGE-102 being in Phase 1 clinical trials. The company's collaboration with Novartis Pharma AG likely enhances its scientific credibility and reputation. A shareholder lawsuit and the abandonment of an obesity drug in March 2025, as well as the reporting of heavy quarterly losses in March 2026, could influence investor perception.

BioAge Labs, Inc. has a diverse ownership structure. There are 117 institutional owners and shareholders holding a total of 21,540,840 shares. Major institutional shareholders include AH Capital Management, L.L.C., Sofinnova Investments, Inc., Octagon Capital Advisors LP, BlackRock, Inc., Vanguard Group Inc, Adage Capital Partners Gp, L.l.c., Orbimed Advisors Llc, Sands Capital Ventures, LLC, Pivotal bioVenture Partners Investment Advisor LLC, and Geode Capital Management, Llc. Andreessen Horowitz LLC holds a 9.0% ownership stake. Private equity firms collectively hold a 20% stake in the company. Individual investors hold 19% ownership. Insiders own 22.29% of the stock. Co-founder and CEO Kristen Fortney owns 3.4% of the company's shares, and Vijay Satyanand Pande is the largest individual shareholder, owning 7.29% of the company's shares. Insiders have sold $4,895,168.00 worth of company stock and made no purchases in the past three months.